Filtered By:
Condition: Psoriasis
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Topical and Oral Roflumilast in Dermatology: A Narrative Review
Actas Dermosifiliogr. 2023 Sep 12:S0001-7310(23)00732-9. doi: 10.1016/j.ad.2023.09.005. Online ahead of print.ABSTRACTOral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case ...
Source: Actas Dermo-Sifiliograficas - September 14, 2023 Category: Dermatology Authors: M Mansilla Polo E Gimeno D Morgado Carrasco Source Type: research
Identification and structural characterization of major stress degradation products of halcinonide by liquid chromatography-high-resolution mass spectrometry
Biomed Chromatogr. 2023 Aug 31:e5730. doi: 10.1002/bmc.5730. Online ahead of print.ABSTRACTHalcinonide is a topical corticosteroid approved by the US Food and Drug Administration (FDA), known for its anti-inflammatory and antipruritic properties. The therapeutic benefits of halcinonide have rendered it an effective treatment regimen for various dermatological conditions such as psoriasis, dermatitis, and eczema. However, stability of the drug substance is a prerequisite in determining the therapeutic efficacy and plays a crucial role during formulation development and long-term storage. As corticosteroids are highly suscep...
Source: Biomedical Chromatography : BMC - August 31, 2023 Category: Biomedical Science Authors: Shivraj Giri Devendra Badgujar Sree Teja Paritala Nitish Sharma Source Type: research
New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 2: Tapinarof
Skinmed. 2023 Aug 28;21(3):177-181. eCollection 2023.ABSTRACTSince its introduction in 1952, topical glucocorticosteroids remain the initial and long-term treatment option for various forms of inflammatory dermatitis. A number of non-steroidal topicals for treating inflammatory dermatoses have been developed in the recent decades (such as topical calcineurin inhibitors, vitamin D analogues, and phophodiesterase-4 inhibitors), but none had the combination of broad therapeutic range, relatively rapid onset of action, high tolerability, and wide-spread clinical success; this allowed topical glucocorticosteroids to remain the ...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Margaret DiRuggiero Elizabeth Mancuso-Stewart Douglas DiRuggiero Matt Zirwas Source Type: research
